Pre-made Relatlimab benchmark antibody ( Whole mAb, anti-LAG3 therapeutic antibody, Anti-CD223 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Relatlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Relatlimab (INN; development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma.
| Products Name (INN Index) | Pre-Made Relatlimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody |
|---|---|
| INN Name | Relatlimab |
| Target | LAG3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Bristol-Myers Squibb,Ono Pharmaceutical,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Conditions Approved | NA |
| Conditions Active | Malignant melanoma,Colorectal cancer,Gastric cancer,Renal cell carcinoma,Solid tumours,Oesophageal cancer,Glioblastoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia,Diffuse large B cell lymphoma,Hodgkin's disease,Mantle-cell lymphoma,Non-Hodgkin's lymphoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | LAG3 |
| Package |
